Our partners are building great companies. We love to share their stories.
Tue, 24 Jan 2023 BioSpace
Polaris Portfolio Companies Named Among Top Life Sciences Startups to Watch in 2023 | BioSpace
Thu, 12 Jan 2023 Ellensburg Daily Record
Wed, 11 Jan 2023 blog.agbiome.com
Mon, 9 Jan 2023 Business Wire
Mon, 9 Jan 2023 GlobeNewswire News Room
Fri, 6 Jan 2023 India - PRNewswire
Thu, 5 Jan 2023 citybiz
Wed, 4 Jan 2023 FierceBiotech
Hummingbird Bio buzzes Synaffix for $150M ADC licensing deal
Mon, 12 Dec 2022 Tessa Therapeutics – Cancer Immunotherapy Treatments
Thu, 8 Dec 2022 PR Newswire
Thu, 1 Dec 2022 businesswire.com
Tue, 29 Nov 2022 Medical Marketing & Media
AstraZeneca expands oncology portfolio with $320M deal for Neogene Therapeutics
Tue, 15 Nov 2022 BioSpace
Thu, 10 Nov 2022 businesswire.com
Mon, 7 Nov 2022 TMCnet.com
Fri, 4 Nov 2022 Drug Discovery and Development
PathAI presents data on using AI to aid liver research and NASH drug development
Mon, 24 Oct 2022 PR Newswire
Cohere Health and Humana Expand Partnership to Further Improve Physician and Member Experiences
Thu, 20 Oct 2022 blog.agbiome.com
Tue, 18 Oct 2022 GlobeNewswire
Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia
Mon, 17 Oct 2022 Business Insider
Polaris Managing Partner Amy Schulman Named by Business Insider as "Top Pioneer in Biotech VC"
Wed, 12 Oct 2022 MobiHealthNews
Tue, 11 Oct 2022 PR Newswire (EN)
Muna Therapeutics Awarded $4.9M Grant from The Michael J. Fox Foundation for Parkinson's Research
Tue, 11 Oct 2022 businesswire.com
Neumora Therapeutics Announces $112 Million Series B Financing
Thu, 6 Oct 2022 PR Newswire
OSF HealthCare Partnering with US HealthVest on new behavioral health hospital
Mon, 26 Sep 2022 fiercehealthcare.com
Fri, 16 Sep 2022 Fortune
PathAI Named to Fortune 2022 Best Workplaces in Biotechnology and Pharmaceuticals
Wed, 14 Sep 2022 BioSpace
Wed, 14 Sep 2022 businesswire.com
Wed, 7 Sep 2022 blog.agbiome.com
AgBiome announces collaboration with W. L. Gore & Associates
Wed, 7 Sep 2022 Freenome
Freenome Launches Study of Multiple Cancers Pairing Multiomics with Real-World Data — Freenome
This website is not an advertisement. This website is intended solely to provide general business information on Polaris Partners and any affiliates thereof (collectively, “Polaris”). Nothing on this website should be construed as an offer of investment advisory services by Polaris or a solicitation or an offer of interests in any Polaris fund. Visitors to this website are not to construe the contents of this website or any prior or subsequent communication from Polaris or any of its representatives, as legal, tax or investment advice. References to specific companies are for illustrative purposes only and do not represent all of the companies recommended for advisory clients. Such references are not intended to be, and should not be interpreted as, recommendations or investment advice. All information has been obtained from sources believed to be reliable, but its accuracy is not guaranteed, and Polaris disclaims any duty to update any of the information and data contained herein. Certain statements may be deemed forward-looking, but any such statements are not guarantees of any future performance and actual results or developments may differ materially from those discussed. There is no guarantee that investment objectives will be achieved or that any particular investment will be profitable. Past performance does not guarantee future results. Where applicable, figures include investments made directly and indirectly by the Polaris Main Funds and may include co-investments with the Polaris Growth Funds and the Polaris Innovation Funds. Please see the complete list of investments here, as well as the Terms of Use for additional information and disclosures.
The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.